CD274 and cancer: In addition, factors such as the diversity of PD-L1 antibodies and platforms, diversity of tissue processing methods, heterogeneity of PD-L1 expression within the same cancer, and heterogeneity between primary cancer metastasis showed that PD-L1 expression was obviously imperfect as a biomarker for pembrolizumab treatment [148].